دورية أكاديمية
TIGIT and CD155 as Immune-Modulator Receptor and Ligand on CD4 + T cells in Preeclampsia Patients.
| العنوان: | TIGIT and CD155 as Immune-Modulator Receptor and Ligand on CD4 + T cells in Preeclampsia Patients. |
|---|---|
| المؤلفون: | Kamrani A; Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.; Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.; Immunology Department, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran., Soltani-Zangbar MS; Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.; Immunology Department, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran., Shiri S; Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran., Yousefzadeh Y; Immunology Department, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran., Pourakbari R; Immunology Department, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran., Aghebati-Maleki L; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran., Mehdizadeh A; Endocrine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran., Danaii S; Gynecology Department, Eastern Azerbaijan ACECR ART Center, Eastern Azerbaijan Branch of ACECR, Tabriz, Iran., Jadidi-Niaragh F; Immunology Department, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran., Yousefi B; Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran., Kafil HS; Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran., Hojjat-Farsangi M; Department of Oncology-Pathology, Immune and Gene Therapy Lab, Cancer Center. Karolinska (CCK), Karolinska University Hospital Solna and Karolinska Institute, Stockholm, Sweden., Motavalli R; Molecular Medicine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran., Zolfaghari M; Molecular Medicine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran., Haji-Fatahaliha M; Immunology Department, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran., Mahmoodpoor A; Department of Anesthesiology, Tabriz University of Medical Sciences, Tabriz, Iran., Ahmadian Heris J; Department of Allergy and Clinical Immunology, Pediatric Hospital, Tabriz University of Medical Sciences, Tabriz, Iran., Emdadi A; Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran., Yousefi M; Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.; Immunology Department, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. |
| المصدر: | Immunological investigations [Immunol Invest] 2022 May; Vol. 51 (4), pp. 1023-1038. Date of Electronic Publication: 2021 Apr 15. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Informa Healthcare Country of Publication: England NLM ID: 8504629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-4311 (Electronic) Linking ISSN: 08820139 NLM ISO Abbreviation: Immunol Invest Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: London : Informa Healthcare Original Publication: New York, N.Y. : M. Dekker, c1985- |
| مواضيع طبية MeSH: | Interleukin-10*/genetics , Interleukin-10*/metabolism , Pre-Eclampsia*, CD4-Positive T-Lymphocytes ; Case-Control Studies ; Cytokines/metabolism ; Female ; Forkhead Transcription Factors/metabolism ; Humans ; Interleukin-17/metabolism ; Leukocytes, Mononuclear/metabolism ; Ligands ; Pregnancy ; RNA, Messenger ; Receptors, Immunologic ; Receptors, Virus ; Transforming Growth Factor beta/metabolism ; Tumor Necrosis Factor-alpha/metabolism |
| مستخلص: | One of the main characteristics of preeclampsia (PE) is systemic inflammation. CD4 + FoxP3 + cells play a critical role in both fetomaternal tolerance and successful pregnancy. T-cell immunoglobulin, as well as immunoreceptor tyrosine-based inhibitory motif (ITIM) domain (TIGIT)/CD155 pathway, possesses critical parts in the development of normal pregnancy by promoting regulatory T (Treg) cells. However, in PE, the relationship between TIGIT/CD155 and Treg differentiation has not been entirely clarified. In the current report, we aimed to assess the frequency of TIGIT and CD155 expressing TCD4 + cells in both PE and healthy pregnant women, as well as evaluating the amount of inflammatory and inhibitory cytokines at both mRNA and protein levels before and after blocking TIGIT and CD155. In the present report, 59 healthy, and 52 PE patients were designated to obtain their venous blood. The isolation of peripheral blood mononuclear cells (PBMCs) was performed from the blood samples, and PBMCs were then cultured in the RPMI1640 medium. The percentage of CD155 + and TIGIT + CD4 + cells was assessed by flow cytometry in PBMCs. Cell culture supernatants were utilized to evaluate the secretory levels of transforming growth factor beta (TGF-β), interleukin (IL)-10, IL-17, tumor necrosis factor alpha (TNF-α), and IL-1 β, using enzyme-linked immunosorbent assay technique in pregnant women with or without PE both before and after blocking TIGIT and CD155. The mRNA expression of Foxp3, TIGIT, CD155, SHP-1, TGF-β, IL-10, IL-17, TNF-α, and IL-1β was also assessed by qRT-PCR in PBMCs before and after blocking TIGIT and CD155 in both populations. The data showed a significant decrease in the frequency of TIGIT + CD4 + and CD155 + CD4 + T cells in PE women, compared to the control group. Our results showed decreased protein and mRNA levels of TIGIT, CD155, IL-10, FOXP3, and SHP-1 in PE patients. In addition, significant improvements in the levels of IL-17, TNF-α, and IL-1β were observed in PE patients, as compared with the controls. However, blocking TIGIT and CD155 could increase these inflammatory cytokines and decrease anti-inflammatory cytokines. The data obtained in this report illustrated that there existed an imbalance between inflammatory and anti-inflammatory profiles, with an inflammatory status polarization, in PE patients. Additionally, TIGIT/CD155 showed a positive effect on immune regulation by activating ITIM, demonstrating the potential therapeutic value of the TIGIT/CD155 pathway in PE treatment. Also, using some proteins or materials that increased TIGIT/CD155 pathways activity and can be a therapeutic approach in PE. |
| فهرسة مساهمة: | Keywords: CD155; Preeclampsia; TIGIT; inflammatory cytokine; regulatory cytokine |
| المشرفين على المادة: | 0 (Cytokines) 0 (Forkhead Transcription Factors) 0 (Interleukin-17) 0 (Ligands) 0 (RNA, Messenger) 0 (Receptors, Immunologic) 0 (Receptors, Virus) 0 (TIGIT protein, human) 0 (Transforming Growth Factor beta) 0 (Tumor Necrosis Factor-alpha) 0 (poliovirus receptor) 130068-27-8 (Interleukin-10) |
| تواريخ الأحداث: | Date Created: 20210415 Date Completed: 20220602 Latest Revision: 20220606 |
| رمز التحديث: | 20240628 |
| DOI: | 10.1080/08820139.2021.1904976 |
| PMID: | 33855917 |
| قاعدة البيانات: | MEDLINE |
PDF full text from Publisher | تدمد: | 1532-4311 |
|---|---|
| DOI: | 10.1080/08820139.2021.1904976 |